Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Mindful movement and skilled attention.

Clark D, Schumann F, Mostofsky SH.

Front Hum Neurosci. 2015 Jun 29;9:297. doi: 10.3389/fnhum.2015.00297. eCollection 2015.

2.

Peak ages of risk for starting nonmedical use of prescription stimulants.

Meier EA.

Drug Alcohol Depend. 2015 Jul 1;152:224-9. doi: 10.1016/j.drugalcdep.2015.03.034. Epub 2015 Apr 9.

PMID:
25908322
3.

Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Somkuwar SS, Kantak KM, Dwoskin LP.

J Neurosci Methods. 2015 Aug 30;252:55-63. doi: 10.1016/j.jneumeth.2015.02.002. Epub 2015 Feb 11.

PMID:
25680322
4.

Methylphenidate treatment beyond adolescence maintains increased cocaine self-administration in the spontaneously hypertensive rat model of attention deficit/hyperactivity disorder.

Baskin BM, Dwoskin LP, Kantak KM.

Pharmacol Biochem Behav. 2015 Apr;131:51-6. doi: 10.1016/j.pbb.2015.01.019. Epub 2015 Jan 31.

PMID:
25643872
5.

Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats.

Baladi MG, Nielsen SM, Umpierre A, Hanson GR, Fleckenstein AE.

Behav Pharmacol. 2014 Dec;25(8):758-65. doi: 10.1097/FBP.0000000000000094.

PMID:
25325290
6.

Stimulant ADHD medication and risk for substance abuse.

Chang Z, Lichtenstein P, Halldner L, D'Onofrio B, Serlachius E, Fazel S, Långström N, Larsson H.

J Child Psychol Psychiatry. 2014 Aug;55(8):878-85. doi: 10.1111/jcpp.12164. Epub 2013 Oct 25.

8.
9.

Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.

Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM.

Drug Alcohol Depend. 2014 Jul 1;140:25-32. doi: 10.1016/j.drugalcdep.2014.04.020. Epub 2014 Apr 28.

10.

Juvenile methylphenidate reduces prefrontal cortex plasticity via D3 receptor and BDNF in adulthood.

Andersen SL, Sonntag KC.

Front Synaptic Neurosci. 2014 Jan 21;6:1. doi: 10.3389/fnsyn.2014.00001. eCollection 2014.

11.

Reducing substance use during adolescence: a translational framework for prevention.

Stanis JJ, Andersen SL.

Psychopharmacology (Berl). 2014 Apr;231(8):1437-53. doi: 10.1007/s00213-013-3393-1. Epub 2014 Jan 25. Review.

12.

Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Stevens JR, Wilens TE, Stern TA.

Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12f01472. doi: 10.4088/PCC.12f01472. Epub 2013 Mar 28. No abstract available.

13.

Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions.

Somkuwar SS, Jordan CJ, Kantak KM, Dwoskin LP.

Neuropsychopharmacology. 2013 Dec;38(13):2588-97. doi: 10.1038/npp.2013.163. Epub 2013 Jul 3.

14.

Chronic Ritalin administration during adulthood increases serotonin pool in rat medial frontal cortex.

Daniali S, Nahavandi A, Madjd Z, Shahbazi A, Niknazar S, Shahbazzadeh D.

Iran Biomed J. 2013;17(3):134-9.

15.

Pediatric psychopharmacology: too much or too little?

Rapoport JL.

World Psychiatry. 2013 Jun;12(2):118-23. doi: 10.1002/wps.20028.

16.

Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies.

Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK.

J Cent Nerv Syst Dis. 2012 Dec 20;5:1-17. doi: 10.4137/JCNSD.S6691. Print 2013.

17.

Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood.

Somkuwar SS, Darna M, Kantak KM, Dwoskin LP.

Biochem Pharmacol. 2013 Jul 15;86(2):309-16. doi: 10.1016/j.bcp.2013.04.013. Epub 2013 Apr 23.

18.

Sympathetic- and parasympathetic-linked cardiac function and prediction of externalizing behavior, emotion regulation, and prosocial behavior among preschoolers treated for ADHD.

Beauchaine TP, Gatzke-Kopp L, Neuhaus E, Chipman J, Reid MJ, Webster-Stratton C.

J Consult Clin Psychol. 2013 Jun;81(3):481-93. doi: 10.1037/a0032302. Epub 2013 Apr 1.

19.

Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group.

J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63. doi: 10.1016/j.jaac.2012.12.014. Epub 2013 Feb 8.

20.

Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Pérez de los Cobos J, Siñol N, Pérez V, Trujols J.

Br J Clin Pharmacol. 2014 Feb;77(2):337-56. doi: 10.1111/bcp.12045. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk